Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

This phase 3 trial tests whether a new drug, TQB2102, works better than the standard treatment (TCbHP) when given before surgery to people with HER2-positive breast cancer. The main goal is to see if the cancer disappears completely by the time of surgery. About 544 participants …

This study tests a new drug called TQB2102 in people with HER2-positive advanced or metastatic biliary tract cancer (bile duct cancer). The goal is to see if the drug is safe and effective. About 102 adults aged 18 to 75 with confirmed HER2-positive tumors will receive the drug. …

This study tests a new drug called TQB2930 combined with chemotherapy against the standard treatment (trastuzumab plus chemotherapy) for people with advanced HER2-positive breast cancer who have already tried at least two prior anti-HER2 therapies. The goal is to see if the new c…

This study tests whether adding an experimental drug (TQB2868) and a targeted therapy (anlotinib) to standard chemotherapy can help people with advanced pancreatic cancer live longer without their cancer growing. About 80 adults with pancreatic ductal adenocarcinoma who have not …

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug is designed to deliver a strong cancer-killing agent directly to tumor cells while sparing healthy tissue. About 270 adults aged 18-…

This early-phase study tests a new drug called TQB6411 in 216 adults with advanced cancers that have not responded to other treatments. The drug is designed to attach to specific markers on cancer cells and deliver a toxin to kill them. The main goals are to find the safest dose …